论文部分内容阅读
1987年1月至1990年1月作者对44例肾移植采用CSA+AZ+Pred作为预防急性排斥(AR)治疗,其中9例发生AR,并对6a-甲基强的松龙(MP)有抗药性,另1例重症AR,共计10例采用OKT-3治疗,其中活体肾移植7例,尸体肾移植3例,男性7例,女性3例,年龄为10～46岁(平均30岁)。开始用药在肾移植后1个月内3例,1～3个月内2例,3月～1年内3例,1年以上2例。OKT-3剂量为5mg/日,连续10天,小儿初次量为3mg/日,在OKT-3使用的7天内停用CSA、AZ继用为50～75mg/日,待第8天后AZ改用CSA。结果: 所有活体肾移植36例中,有12例20次发生
From January 1987 to January 1990, 44 renal transplant recipients were treated with CSA + AZ + Pred as a prophylaxis for acute rejection (AR), 9 of whom developed AR and 6 a-methylprednisolone 10 cases were treated with OKT-3, including 7 cases of living kidney transplantation and 3 cases of cadaveric kidney transplantation. There were 7 males and 3 females, aged from 10 to 46 (average 30 years old) . Three months after transplantation, 2 cases within 1 ~ 3 months, 3 cases between 1 month and 1 year and 2 cases more than 1 year after the start of treatment. OKT-3 dose of 5mg / day for 10 days, the initial amount of children 3mg / day, OKT-3 in the use of the 7-day withdrawal of CSA AZ AZ 50775mg / day, until the eighth day after the use of AZ CSA. RESULTS: Of the 36 cases of all living kidney transplants, 12 developed 20 times